Answers are grounded in this paper and cite their sources.
A novel ansamycin, rifamycin W, was isolated from a mutant strain of Nocardia mediterranei. The metabolic origin of rifamycin W was studied by (13)C nuclear magnetic resonance spectroscopy. Examination of the proton-decoupled pulse and Fourier transform (13)C spectra of rifamycin W biogenetically enriched with [1-(13)C]-, [2-(13)C]-, and [3-(13)C]propionate and with [1-(13)C]acetate has revealed that the alignment of acetate and propionate units corresponds to that previously proposed for rifamycin S. Washed mycelium from a rifamycin B-producing strain of N. mediterranei transformed rifamycin W into rifamycin B. We suggest that rifamycin W is a normal intermediate in the biosynthesis of the other rifamycins. These results, together with the structural similarity of rifamycin W to the streptovaricins, reinforce our hypothesis that a common progenitor is involved in the biogenesis of all naphthalenic ansamycins.
No takes yet. Share an insight, caveat, or question.
White et al. (1974) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: